Antifungal Therapy with Azoles Induced the Syndrome of Acquired Apparent Mineralocorticoid Excess: a Literature and Database Analysis-Reference-Cited by-同舟云学术

Antifungal Therapy with Azoles Induced the Syndrome of Acquired Apparent Mineralocorticoid Excess: a Literature and Database Analysis

Published:2022-01-18 Issue:1 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ji Huan-huan¹^ORCID,Tang Xue-wen²,Zhang Ni¹,Huo Ben-nian¹,Liu Ying³,Song Lin¹,Jia Yun-tao¹^ORCID

Affiliation:

1. Department of Pharmacy, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, China

2. Chengdu Shuchuang Linyan Technology Co., Ltd, Chengdu, China

3. Department of Pharmacy, National Center for Children‘s Health, Beijing Children’s Hospital, Capital Medical University, Beijing, China

Abstract

We aimed to estimate the risk of varied antifungal therapy with azoles causing the syndrome of acquired apparent mineralocorticoid excess (AME) in real-world practice. First, we conducted a disproportionality analysis based on data from the FDA Adverse Event Reporting System (FAERS) database to characterize the signal differences of triazoles-related AME.

Funder

Chongqing Medical University

Chongqing Municipal Education Commission

Chongqing Municipal Public Health Bureau, Chongqing People's Municipal Government

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01668-21

Reference28 articles.

1. Classic and Nonclassic Apparent Mineralocorticoid Excess Syndrome